Therpeutic drug monitoring of Everolimus in patients with renal cell carcinoma and tuberous sclerosis

Trial Profile

Therpeutic drug monitoring of Everolimus in patients with renal cell carcinoma and tuberous sclerosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Angiomyolipoma; Renal cell carcinoma; Tuberous sclerosis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms TDM study of Everolimus
  • Most Recent Events

    • 03 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top